Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK39004 in COPD
NCT07108699Phase 2Active, not recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HSK39004 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Change from baseline in Forced Expiratory Volume in 1 second Area Under the Curve from 0 to 12 hours. Started Aug 2025; status: active, not recruiting.
02
Drugs
HSK39004
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07108699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108699.